Polysaccharides from Chinese Herbal Lycium barbarum Induced Systemic and Local Immune Responses in H22 Tumor-Bearing Mice

Lycium barbarum polysaccharide (LBP) is isolated from the fruit of Chinese herbal Lycium barbarum. Previous studies had demonstrated that LBP could inhibit tumor growth and enhance the immunity in mice. However, the effect of LBP on systemic and local immune responses in vivo, especially on phenotypic and functional changes of T cells, is still largely unknown. In the present study, we investigated the effects of LBP on systemic and local T cell-dependent antitumor immune responses in H22 tumor-bearing mice. The results showed that LBP could inhibit the solid tumor growth in mice, but showed little effect on the body weight or spleen index. Furthermore, LBP could maintain high levels of T cells in peripheral blood (PB), tumor draining lymph node (TDLN), and tumor tissue, prevent the increase of Tregs while promote infiltration of CD8+ T cells in tumor tissue, inhibit the production of TGF-β1 and IL-10 in serum, decrease the exhaustion phenotype of T cells, and maintain cytotoxicity of lymphocytes. Taken together, our results demonstrated that LBP simultaneously induced systemic and local immune responses in H22 tumor-bearing mice by alleviating immunosuppression and maintaining antitumor immune responses in mice.

[1]  Ana Cumano,et al.  CD25+ CD4+ T Cells Regulate the Expansion of Peripheral CD4 T Cells Through the Production of IL-101 , 2001, The Journal of Immunology.

[2]  S. Luo,et al.  Antitumor activity of Lycium barbarum polysaccharides with different molecular weights: an in vitro and in vivo study , 2017, Food & nutrition research.

[3]  T. Oshikiri,et al.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.

[4]  Y. Li,et al.  PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients , 2014, British Journal of Cancer.

[5]  Gisen Kim,et al.  Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis , 2009, Nature Immunology.

[6]  F. Ghiringhelli,et al.  Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.

[7]  Xia Luo,et al.  Effects of ceftriaxone induced intestinal dysbacteriosis on lymphocytes in different tissues in mice. , 2016, Immunobiology.

[8]  F. Wang,et al.  Characterization of Lycium barbarum polysaccharide and its effect on human hepatoma cells. , 2013, International journal of biological macromolecules.

[9]  M. Smyth,et al.  CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1 , 2006, The Journal of Immunology.

[10]  Liang Zhou,et al.  Neuroprotective effects of Lycium barbarum polysaccharides in lipopolysaccharide-induced BV2 microglial cells. , 2013, Molecular medicine reports.

[11]  Yun Chen,et al.  Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells , 2014, Cellular and Molecular Immunology.

[12]  W. Han,et al.  Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy , 2016, Journal of the National Cancer Institute.

[13]  M. Neurath,et al.  Cutting Edge: TGF-β Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells1 , 2004, The Journal of Immunology.

[14]  Jie Zhu,et al.  Lycium barbarum polysaccharides regulate phenotypic and functional maturation of murine dendritic cells , 2007, Cell biology international.

[15]  T. Whiteside,et al.  Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.

[16]  Thomas M. Schmitt,et al.  Re‐adapting T cells for cancer therapy: from mouse models to clinical trials , 2014, Immunological reviews.

[17]  Yong Zhao,et al.  Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes , 2011, Cellular and Molecular Immunology.

[18]  Shumei Yan,et al.  PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis , 2017, Journal of Cancer.

[19]  Jinliang Peng,et al.  Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharides through the suppression of oxidative stress. , 2011, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[20]  Zhiyong Wu,et al.  Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer , 2015, Chinese medical journal.

[21]  Wen-xia Zhou,et al.  Lycium barbarum polysaccharide LBPF4-OL may be a new Toll-like receptor 4/MD2-MAPK signaling pathway activator and inducer. , 2014, International immunopharmacology.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  D. Mullins,et al.  Tumor cell‐derived TGF‐β and IL‐10 dysregulate paclitaxel‐induced macrophage activation , 2001, Journal of leukocyte biology.

[24]  L. Gan,et al.  Immunomodulation and antitumor activity by a polysaccharide-protein complex from Lycium barbarum. , 2004, International immunopharmacology.

[25]  R. G. van der Most,et al.  Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies , 2012, British Journal of Cancer.

[26]  S. Akira,et al.  Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals1 , 2006, The Journal of Immunology.

[27]  Zhenguang Liu,et al.  Simple nanoliposomes encapsulating Lycium barbarum polysaccharides as adjuvants improve humoral and cellular immunity in mice , 2017, International journal of nanomedicine.

[28]  V. Engelhard,et al.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. , 2015, Advances in cancer research.

[29]  Han-Wei Lin,et al.  Depletion of Regulatory T Lymphocytes Reverses the Imbalance between Pro- and Anti-Tumor Immunities via Enhancing Antigen-Specific T Cell Immune Responses , 2012, PloS one.

[30]  S. Chan,et al.  Activation of T lymphocytes by polysaccharide-protein complex from Lycium barbarum L. , 2008, International immunopharmacology.

[31]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[32]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[33]  D. Cohen,et al.  CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. , 2008, Immunology letters.

[34]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[35]  Chun-Hong Zhao,et al.  Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo , 2015, Molecular medicine reports.

[36]  H. Nawata,et al.  TGF-β1 Plays an Important Role in the Mechanism of CD4+CD25+ Regulatory T Cell Activity in Both Humans and Mice , 2004, The Journal of Immunology.

[37]  Xiao-rui Zhang,et al.  Immune activities comparison of polysaccharide and polysaccharide-protein complex from Lycium barbarum L. , 2014, International journal of biological macromolecules.

[38]  Tao-Tao Liu,et al.  Hepatocellular Carcinoma Cells Induce Regulatory T Cells and Lead to Poor Prognosis via Production of Transforming Growth Factor-β1 , 2016, Cellular Physiology and Biochemistry.

[39]  J. Myśliwska,et al.  CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. , 2006, Clinical immunology.

[40]  S. Ansell,et al.  Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. , 2006, Cancer research.

[41]  N. Mount,et al.  Genetically modified T cells in cancer therapy: opportunities and challenges , 2015, Disease Models & Mechanisms.

[42]  D. Fowell,et al.  CTLA‐4 is required by CD4+CD25+ Treg to control CD4+ T‐cell lymphopenia‐induced proliferation , 2009, European journal of immunology.

[43]  M. Werner,et al.  Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes , 2009, British Journal of Cancer.